Search - tctmd.com

Displaying 201 - 220 of 796

Sort: Relevancy | Date

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

COVID-19: TCTMD’s Dispatch for October Week 2

News Daily News

COVID-19: TCTMD’s Dispatch for October Week 2

October 11, 2021

Valve-in-Valve TAVI Bests Redo SAVR in Short Term

News Daily News

Valve-in-Valve TAVI Bests Redo SAVR in Short Term

Michael O'Riordan

September 20, 2021

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

News Conference News ESC 2021

2021 ESC/EACTS Valve Guidelines Unveil TAVI/SAVR Age Cutoffs and Earlier Care

August 31, 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

News Conference News ESC 2021

Amulet IDE: LAA Occluder Performs Well Against Watchman

August 30, 2021

ACST-2: Carotid Stenting, Surgery Provide Similar Outcomes in Asymptomatic Patients

News Conference News ESC 2021

ACST-2: Carotid Stenting, Surgery Provide Similar Outcomes in Asymptomatic Patients

August 29, 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

News Conference News ESC 2021

ENVISAGE-TAVI AF: Edoxaban Disappoints in TAVI Setting

August 28, 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

August 28, 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

August 19, 2021

FDA Approves Amplatzer Amulet LAA Occluder

News Daily News

FDA Approves Amplatzer Amulet LAA Occluder

August 17, 2021

Short-term LAA Occlusion Outcomes Worse in Women

News Daily News

Short-term LAA Occlusion Outcomes Worse in Women

August 17, 2021

Marijuana Ups Bleeding, CVA Risks in PCI Patients: Registry Data

News Daily News

Marijuana Ups Bleeding, CVA Risks in PCI Patients: Registry Data

August 16, 2021

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

News Daily News

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

August 04, 2021

STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation

News Conference News HRS 2021

STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation

July 29, 2021

News Industry News

Medtronic TYRX™ Absorbable Antibacterial Envelope Is Effective at Reducing Infections in Cardiac Device Patients with Hematomas

July 26, 2021

Predictors of Device-Related Thrombus Following LAA Occlusion

News Daily News

Predictors of Device-Related Thrombus Following LAA Occlusion

July 19, 2021

De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis

News Daily News

De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis

Yael L. Maxwell

July 16, 2021

Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists

News Daily News

Studies Explore Post-MI Use of Beta-blockers, Mineralocorticoid Receptor Antagonists

July 09, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.